ADAPY Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Adaptimmune Therapeutics PLC

Watchlist Manager

Watchlist

Price: 0.027 USD -6.9% Market Closed

Market Cap: $42.9m

	Adaptimmune Therapeutics PLC OTC:ADAPY	UK

Profitability Summary

Adaptimmune Therapeutics PLC's profitability score is 5/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin

32%

Sustainable 3Y Average Gross Margin

17%

Negative Operating Margin

-223%

Negative 3Y Average Operating Margin

-219%

Declining Operating Margin

-158% > -223%

Negative Net Margin

-261%

Negative 3Y Average Net Margin

-204%

Declining Net Margin

-129% > -261%

Negative Free Cash Flow Margin

-296%

Negative 3Y Average Free Cash Flow Margin

-206%

Declining Free Cash Flow Margin

-204% > -296%

Negative ROE

-1 341%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-91%

Declining ROIC

-97% > -153%

View All

Hide

Collapse

5 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.